This page summarises the type of evidence that exists for PE-22-28. It is not a systematic review and does not cite specific trials.
Overview
PE-22-28 appears in the scientific literature as a spadin analog developed to probe the TREK-1 potassium channel and its relationship to mood. Its evidence base is early-stage and centered on preclinical neuroscience rather than human clinical medicine, which shapes how cautiously its effects should be described.
Mechanistic and channel research
A core body of work explores how spadin and its analogs interact with TREK-1 (KCNK2) and what that means for neuronal signaling. Studies in this area have examined:
- Inhibition of the TREK-1 background potassium channel.
- Effects on neuronal excitability in mood-associated brain regions.
- Markers of neuroplasticity linked to antidepressant-like activity.
Preclinical behavioral studies
Beyond channel biology, PE-22-28 has been studied in animal behavioral models used to screen for antidepressant-like effects. Interest in these studies has focused on the speed of onset, since a faster response than conventional agents is the compound's most discussed feature. These are rodent findings, not human results.
The translational gap
A defining feature of the PE-22-28 evidence base is the gap between promising animal data and the absence of established human trials. Many compounds that look encouraging in rodents do not reproduce their effects in people, and PE-22-28 has not yet crossed that threshold. This gap is central to interpreting any claim about the compound.
Context and caveats
PE-22-28 is not an FDA-approved therapy anywhere, and long-term human outcome data do not exist. When reviewing the literature, consider study design, the species studied, endpoints, and how far the setting is from real-world clinical use. Marketing narratives frequently move faster than the evidence supports, and depression remains a condition that requires qualified clinical care.